NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

Model scores of the 29,894 trials active now.

Model score 34% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellulnpazopanibcoronaryregistration
  Phrases that lowered it: kidneysorafenibparticipantweeksclinical trial
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 20.2% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Keywords listed: 11 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 194 (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 82.7% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC) NCT01263769 · started 2011 · scored riskier than 98% of active trials completed
• Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study) NCT03456401 · started 2014 · scored riskier than 73% of active trials terminated
• A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus NCT01798446 · started 2013 · scored riskier than 45% of active trials completed
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer NCT04337970 · started 2020 · scored riskier than 60% of active trials completed
• Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion NCT03494816 · started 2017 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.